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months of the index date including the index date (cohort
Cnn), patients with no CHF but MI or stroke (cohort Cny),
patients with CHF but no MI or stroke (cohort Cyn), and
patients with both CHF and MI or stroke (cohort Cyy).
RESULTS: Number of patients identified for cohorts Cnn,
Cny, Cyn and Cyy were 319, 91, 195 and 59; among them
52%, 41%, 52%, and 47% were female, respectively.
The mean ages of patients in cohorts Cnn, Cny, Cyn and Cyy
were 68.5, 73.5, 75.2, and 76, respectively. The follow-
ing table shows the hospital utilization (percent of AF/F
patients hospitalized for any reason):
CONCLUSIONS: Cost intensive resource utilization, such
as hospitalization, increases up to 139.3% after the diag-
nosis of AF/F as recorded in a managed care claims data-
base. Although patients with concomitant illnesses, such
as CHF, MI, and stroke, have higher hospital utilization
compared to patients without such diseases, AF/F con-
tributes to the highest percentage increase for the healthi-
est patient population.
PCV9
COST-COMPARISON ANALYSIS OF HOME-
MONITORING AND AMBULANT MONITORING 
OF ORAL ANTICOAGULATION
IN SWITZERLAND
Neeser K, Weiss C, Brandt A, Palmer AJ
IMIB, Institute for Medical Informatics and Biostatistics, Basel, 
Switzerland
BACKGROUND: A disease model was developed to com-
pare clinical and economic outcomes of home monitoring
versus ambulant monitoring in anticoagulation patients
with heart valve implants in two different locations. The
improved outcomes seen with home monitoring result from
tighter control of the anticoagulation (AC) level. Thereby a
higher proportion of patients is kept within the therapeutic
INR target range leading to a decreased incidence of ad-
verse events.
OBJECTIVE: The model compares the event-rates of ma-
jor thromboembolic events (TE), major bleeding (BL) com-
plications and mortality rates in cohorts with mechanical
heart valve replacement requiring oral anticoagulation with
warfarin.
METHODS: The AC monitoring strategies compared
were A) 52 times/year home monitoring of AC with the
CoaguChek home-monitor, and B) monthly monitoring
in an outpatient clinic (with laboratory tested AC levels).
Direct costs of basic treatment, patient education and mon-
itoring, as well as treatment costs of complications were
collected from the Swiss third party payer perspective. Com-
plication rates (TE, BL, mortality) were derived from pub-
lished literature and official agency reports. The health eco-
nomic analysis simulated an observational time of 10 years.
Cost outcomes were discounted at a real annual rate of 5%.
RESULTS: Self-monitoring by patients reduces the total
costs (monitoring and complication related costs) per pa-
tient from Swiss Francs (CHF) 8’988 to CHF 7’532 per pa-
tient over the observation time of 10 years. Sensitivity anal-
ysis were performed and identified the main cost drivers as:
frequency of home monitoring, cost per home monitoring
test, cost and durability of home monitoring device.
CONCLUSION: Demonstrated within the limitations of
the modelling approach, the application of home monitor-
ing in heart valve implant patients is dominant to ambulant
monitoring in outpatient clinics, with increased life quality
and decreased overall costs.
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PREDICTORS OF ADHERENCE TO LIPID-
LOWERING THERAPY
de Vries CS, Donnan PT, Waugh N, MacDonald TM
University of Dundee, Medicines Monitoring Unit, Dundee, 
Scotland
BACKGROUND: High serum lipid levels are an impor-
tant risk factor for cardiovascular disease such as myocar-
dial infarction and stroke. Recently, an American study
demonstrated that 5 years after beginning treatment, ap-
proximately half of the cohort studied had stopped statin
therapy.1 The aim of our study was to estimate adherence
to statins in Tayside and to determine if co-morbidity, so-
cial deprivation, and co-prescribing were predictors of ad-
herence.
METHODS: Two studies were performed: Study 1, to de-
termine adherence to statins over a 5-year period of follow-
up and predictors of that adherence. Study 2, to find pre-
dictors of compliance with statins in a 13-month follow-up
period after publication of the 4S-study.2 The study popula-
tion consisted of all individuals from the fixed population
base who received more than one prescription for a statin.
For each individual, adherence to therapy was defined as
the days for which statins had been dispensed divided by
the number of days they should have been dispensed. Peo-
ple who had statins dispensed for 85% or more of their
days in the community were classified as adherent. Logistic
regression analyses were performed to determine predictors
of short-term and long-term adherence.
RESULTS: Study 1. After 5 years, 65% of the original co-
hort (n  392) were still collecting prescriptions for statins.
89 (23%) were adherent to statin therapy. Predictors of
adherence were cardiovascular disease (OR: 1.19), female
gender (OR 1.67), and co-prescribing of nitrates (OR
1.62). Study 2. Of the 1548 people who received a statin,
652 (42%) were adherent to therapy. In this study, predic-
tors were age (OR 1.02), use of nitrates (OR 0.76), and di-
abetes (OR 0.65).
Cnn Cny Cyn Cyy Total
Before index date 13.5 35.2 33.9 47.5 25.5
After index date 32.3 42.9 57.4 54.2 43.1
Percent increase 139.3 21.9 69.3 14.1 69.0
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DISCUSSION: The majority of people that were treated
with statins stayed on these drugs although they used less
than was prescribed to them. Adherence to statins in-
creased over the years, however patients became less adher-
ent the longer they used them.
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STUDY OF HEALTH CARE RESOURCE USE FOR 
ELDERLY PATIENTS WITH MILD AND 
MODERATE ARTERIAL HYPERTENSION
Geltzer B, Frisman M
Vladivostok State Medical University, Vladivostok, Russia
OBJECTIVES: To study health care expenditures for pa-
tients with arterial hypertension.
METHODS: We observed elderly patients (n  186; mid-
dle age 68,4  2,2 years) from January 1997 to May 1999.
We investigated four medicines from the basic groups of
hypotensive drugs: nifedipine-GITS; enalapril; diltiazem;
indapamide. We defined duration of hospital treatment,
number of ambulant visits and emergency care.
RESULTS: Before treatment the middle number of ambu-
lant visits was 6,01 per year. Against a background of
monotherapy the number of visits was decreased: in nife-
dipine-GITS group (NG)—to 2,75 (CI 1,2–2,4); in enala-
pril group (EG)—to 3,27 (CI 1,5–3,1); in diltiazem group
(DG)—to 3,76 (CI 1,4–2,3); in indapamide group (IG)—to
5,28 (CI 1,4–3,2). Expenditures of health care were dimin-
ished: in NG—by 54,53%; in EG—by 46,14%; in DG—by
37,82%; in IG—by 12,69%. Before the treatment the mid-
dle duration of hospital treatment was 22,84 days. Against
a background of monotherapy the duration of hospital
treatment was decreased: in NG—to 14,25 days (CI 1,74–
3,48); in EG—to 16,63 days (CI 1,35–3,21); in DG—to
15,76 days (CI 1,42–3,38); in IG—to 16,57 days (CI 1,41–
3,23). Expenditures of health care were diminished: in
NG—by 37,62%; in EG—by 27,2%; in DG—by 31,01%;
in IG—by 27,47%. Combined economy in NG was
48,2%; in EG—27,76%; in DG—36,61%; in IG—32,3%.
RESULTS: This investigation provides comparative evalu-
ation of economy of health care resource with different
medicines.
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ECONOMIC EVALUATION OF ACE INHIBITORS 
IN SPAIN
Asensio J, Hermida H, Abbas I
Kendall Institute, Barcelona, Spain
OBJECTIVES: To evaluate which ACE inhibitor, of the
10 that are marketed in Spain, offers the most favorable
cost-effectiveness relationship in the treatment of light-
moderate arterial HBP.
MATERIAL AND METHODS: Only direct costs derived
from treatment were taken into consideration. We have
calculated the cost of treatment per day (CTD) in the fol-
lowing way: By grouping the different pharmaceutical
products marketed in Spain by active ingredients. The price
of the daily defined dose (DDD) was established for each
product by dividing its price by the number of tablets that
the DDD requires in accordance with the recommended
dose in the information leaflet.
RESULTS: In more or less objective terms it is accepted
that therapeutic efficiency within the group of ACE inhibi-
tors is very similar and so efficiency depends exclusively on
the cost of the product. This has lead to the carrying out of
an analysis of the minimization of costs, and this shows
that the alternative with the lowest cost per controlled pa-
tient is Enalapril, so substituting this option for the rest of
ACE inhibitor prescriptions could result in very significant
savings. Potential savings could reach 10,801 Million Ptas.
per annum if the lower priced Enalapril were used.
CONCLUSIONS: Enalapril is the most cost-effective ACE
inhibitor for the treatment of light and moderate HBP in
Spain. Substituting Enalapril for prescriptions for the rest
of ACE inhibitors could lead to a significant saving poten-
tial in pharmaceutical spending. Changing to lower priced
Enalapril could increase the figure for potential savings by
up to almost 11,000 Million Ptas. per annum which makes
it the most efficient option.
ECONOMIC AND OUTCOMES ISSUES OF 
ENDOCRINE DISORDERS
PEN1
QUALITY-OF-LIFE-EVALUATION OF THE 
GERMAN S.A.T.-TRIAL - COMPARISON OF SF-36, 
EUROQOL, TIME-TRADE-OFF METHOD AND 
WILLINGNESS-TO-PAY
Wendland G, Kurscheid T, Lauterbach KW
University of Cologne, Köln, Germany
OBJECTIVE: To assess the effectiveness of evidence-based
treatment of obesity in a primary care setting, we con-
ducted the S.A.T.-trial (Sibutramine in Adiposity Trial)
which is a multicenter, double-blind, placebo-controlled,
randomized parallel group comparison of 54-week contin-
uous therapy with Sibutramine 15 mg or Placebo in addi-
tion to a standardized non-pharmacological therapy con-
sisting of a calorie-restricted diet, modification of eating
behavior and lifestyle, and an activity programme. Patients
with a BMI between 30 and 40 are included. The primary
endpoint in this study is weight loss in kg between the last
measurement of body weight (visit 11) and the measure-
ment at the first visit. Secondary endpoints are amongst
other clinical parameters health economic and quality of
life data. Since the random code is still not broken, the re-
sults given in this abstract refer to all randomized obese
patients in the study (both Sibutramine and placebo
group). The presentation in November will show the re-
sults for the two patient groups separately.
QUALITY OF LIFE MEASURES: Quality of life is mea-
sured by 4 different instruments: the Short Form 36 (SF-36):
the EuroQol, the Time-trade-off-Method (TTO) and the
Willingness-to-pay-Method (WTP). The SF-36 is a general,
